IL17A and myeloid sarcoma: IL17A, a key cytokine of Th17, has also demonstrated efficacy against MS in a pilot study with its antibody, sekukinumab34, while the blockade of IL-17A ameliorated the disease symptoms in various models of EAE mice40,41.